Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition

These findings allow the identification of a subset of patients that will be responsive to c-MET inhibition and propose ligand pretreatment as a potential new strategy for improving the anticancer efficacy of RTK inhibitors.